Bristol Myers to sell psoriasis drug at over 80% discount

Bristol Myers Squibb (BMY) announced it will sell its psoriasis drug Sotyktu directly to cash-paying U.S. patients at an 86% discount, lowering the monthly cost from $6,828 to $950, beginning in January. This direct-to-patient program, bypassing traditional pharmacy benefit managers and insurers, targets uninsured or underinsured individuals and comes amid sustained pressure from the Trump administration to reduce drug prices, potentially signaling a broader shift in pharmaceutical distribution and pricing models.

Analysis

Bristol Myers Squibb (BMY) is launching a direct-to-patient program for its psoriasis drug Sotyktu, implementing a substantial 86% discount that lowers the monthly cost from $6,828 to $950 for uninsured or underinsured U.S. patients. This strategic maneuver, initiated amid pressure from the Trump administration on drug pricing, utilizes a new platform, BMS Patient Connect, to bypass traditional pharmacy benefit managers and insurers. While the company specifies the program targets a "small percentage" of patients, suggesting a limited immediate impact on total revenue, the move is significant. It expands on a similar direct-selling model BMY and partner Pfizer (PFE) use for their blockbuster drug Eliquis, which offers a more modest discount of over 40%. The negative sentiment signal for BMY (-0.5) reflects investor apprehension regarding margin compression and the precedent set by yielding to political pressure, even if the direct financial exposure from this specific program is contained for now.

Key Decisions for Investors

• Investors should monitor for any further expansion of direct-to-patient models, as this signals a potential long-term strategic shift to disintermediate pharmacy benefit managers, which could alter the industry's profit structure.
• The significant 86% discount on Sotyktu, while limited to a small patient cohort, should be viewed as a material indicator of the escalating political and regulatory risk to pharmaceutical pricing power, warranting a re-evaluation of long-term margin assumptions.
• Consider this action a strategic concession to political pressure with limited immediate financial downside, but remain cautious as the model could be expanded to other drugs or a larger patient base if regulatory pressures intensify.